QuantRx Biomedical Corp. (QTXB.OB) Further Expands Its Intellectual Property Suite
QuantRx Biomedical Corp., a diagnostic company focused on developing and commercializing innovative diagnostic products, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent extending its lateral flow testing intellectual property suite. This new patent will add significant protection as QuantRx enters the market with its hypersensitive point-of-care lateral flow based system. Together with the patented Q-reader technology, QuantRx is able to provide CLIA (Clinical Laboratory Improvement Amendments) waived Point-of-Care (POC) tests that other technologies cannot offer. “This milestone event for QuantRx marks the culmination of over a decade of research by our exceptional R&D…